行情

ALXN

ALXN

亚力兄制药
NASDAQ

实时行情|Nasdaq Last Sale

104.85
+2.36
+2.30%
盘后: 105.23 +0.38 +0.36% 17:13 08/03 EDT
开盘
102.67
昨收
102.49
最高
105.13
最低
101.75
成交量
139.80万
成交额
--
52周最高
125.52
52周最低
72.67
市值
231.54亿
市盈率(TTM)
28.09
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALXN价格均价为141.47,最高价位175.00,最低价为114.00。

EPS

ALXN 新闻

更多
Alexion Pharmaceuticals (ALXN) Q2 2020 Earnings Call Transcript
MotleyFool.com · 3天前
Got $200? Here Are 3 Smart Stocks to Invest in Now
MotleyFool.com · 3天前
10 Biggest Biotechnology Companies
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
Investopedia · 4天前
Alexion beats Q2 consensus; revenue guidance raise tops estimates
Alexion Pharmaceuticals (ALXN) Q2 results: Revenues: $1,444.6M (+20.1%); Soliris: $975.5M (-0.5%); Ultomiris: $251.1M (+363.3%); Strensiq: $184.3M (+30.4%)
seekingalpha · 4天前
What's Behind Alexion Pharmaceuticals' Strong Q2 Results
Alexion Pharmaceuticals (NASDAQ: ALXN) stock has been on a big roll over the last few months. Alexion announced a net loss in Q2 of $1.1 billion, or $4.84 per share, based on generally accepted accounting principles (GAAP). Alexion recorded adjusted non-GAAP
Motley Fool · 4天前
Alexion Pharmaceuticals EPS beats by $0.53, beats on revenue
Alexion Pharmaceuticals (NASDAQ:ALXN): Q2 Non-GAAP EPS of $3.11 beats by $0.53; GAAP EPS of -$4.84 misses by $6.97. Revenue of $1.44B (+20.0% Y/Y) beats by
seekingalpha · 4天前
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Zacks · 4天前
Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates
Alexion (ALXN) delivered earnings and revenue surprises of 21.96% and 14.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4天前

所属板块

制药
+1.51%
制药与医学研究
+2.08%

热门股票

代码
价格
涨跌幅

ALXN 简况

Alexion Pharmaceuticals, Inc.是一家生物医药公司。该公司专注于开发及销售人体疾病治疗产品。该公司从事人体疾病治疗产品的创新、开发及商业化业务。其上市产品包括Soliris (eculizumab)、Strensiq(asfotase alfa)及Kanuma(sebelipase alfa)。其临床研究产品包括Soliris (eculizumab)、ALXN 1101、 ALXN 1007、 SBC-103、 ALXN 1210及ALXN 5500。Soliris用于治疗阵发性夜间血红蛋白尿症(一种威胁生命的罕见遗传血液疾病)及非典型溶血尿毒综合征(一种威胁生命的罕见遗传病)。Strensiq是定向酶替代治疗产品。Kanuma用于治疗溶酶体酸脂肪酶匮乏症。ALXN 1007是用于治疗炎症的人源化抗体。
展开

微牛提供Alexion Pharmaceuticals, Inc.(NASDAQ-ALXN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALXN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALXN股票基本功能。